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Abstract: Pheochromocytoma (PCC) and sympathetic paraganglioma (PGL) are rare neuroendocrine
tumors characterized by catecholamine production in the adrenal medulla and extra-adrenal
paraganglia. PCC and PGL (PPGL) with metastasis was termed malignant PPGL. However,
the distinction between “benign” and “malignant” PPGLs has been debated. Currently, all PPGLs
are believed to have some metastatic potential and are assigned malignant tumors (ICD-O/3) by the
WHO Classification of Endocrine Organs (2017, 4th edition). Therefore, the previous categories benign
and malignant PPGL have been eliminated in favor of risk stratification approach. The Grading of
Adrenal Pheochromocytoma and Paraganglioma (GAPP) is a tool for risk stratification for predicting
metastasis and the prognosis of patients. At least 30% of PPGLs are hereditary, with 20 genes
identified and genotype-phenotype correlations clarified. Of these genes, VHL, RET and NF1 have
been well investigated and are the primary cause of bilateral PCC. In addition, mutation of succinate
dehydrogenase gene subunits SDHB and SDHD are strongly correlated with extra-adrenal location,
younger age, multiple tumors, metastasis and poor prognosis. Disease stratification by catecholamine
phenotype and molecular profiling correlates with histological grading by GAPP. PPGLs should be
understood comprehensively based on clinical, biochemical, molecular and pathological data for
patient care. A flow chart for pathological diagnosis is included.
Keywords: pheochromocytoma; paraganglioma; GAPP; metastasis; prognosis; catecholamine;
gene mutation; immunohistochemistry; pathology; diagnosis
1. Introduction
Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors that arise
in the adrenal medulla and the extra-adrenal paraganglia, respectively. There are two types of PGL,
parasympathetic and sympathetic. Both PCC and sympathetic PGL are catecholamine-producing
tumors, which often have a common genetic basis and functional similarities. The incidence of
PCC and PGL (PPGLs) is 1–3 individuals per 100,000, with 500–1600 new cases in the United States
per year [1,2]. Most PCC present in the fourth to fifth decades of life, with a roughly equal sex
distribution. The incidence of PGL is 10–15% that of PCC. PPGLs are characterized by their broad
age of incidence, familial association, multifocal tendency and metastasis. At least 30% of PPGLs
are hereditary and susceptible genes have been identified [1,2]. A prolonged hypoxic state such as
Eisenmenger’s syndrome may be related to PPGL pathogenesis [3]. The risk of metastasis is 10–20% in
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PCC and up to 50% in PGL depending on the genotype [4–6]. The data presented here are primarily
regarding PCC and sympathetic PGLs.
Since the beginning age of PPGL research about 50 years ago [7], PPGLs have been classified
into either benign or malignant tumors. Despite of much research, there are no universally acceptable
histologic criteria predicting metastasis. Thus, histology has been considered useless for differentiating
between benign and malignant tumors; malignant PCC was defined only by the presence of metastasis
(World Health Organization (WHO), 2004) [8]. The lack of a histological, molecular, or genetic criteria
that can absolutely differentiate between benign and malignant PCC/PGL presents an enormous
clinical challenge [9]. As a result, the European Clinical Guideline decided that all patients with PPGLs
should be followed up for at least 10 years and high-risk patients (young, genetic disease, large tumor
and PGL) should be offered lifetime annual follow ups [10].
Japan was found to have a similar situation. A nationwide survey of PPGLs determined
in 2010 that 2920 patients had PPGLs, 320 of which had metastases [11]. Among patients with
320 malignant PPGL, 37% were initially diagnosed as benign and 60% showed absence of metastasis at
initial operation. It was concluded from these results that the diagnosis of benign is not correct for
PPGLs with no metastasis at the time of the initial operation and long-term follow up is necessary
for patients with PPGL even though the pathologic diagnosis is benign. Based on such clinical data,
the WHO Endocrine Tumor Classification 4th edition (2017) [1,2] [decided on a New Concept that all
PPGLs have some metastatic potential and assigned an International Classification of Diseases for
Oncology (ICD-O)-3 (malignant tumors) for all PPGLs, eliminating the previous categories of benign
and malignant tumors in favor of an approach based on risk stratification [1,2]. Risk stratification is
required to tailor the follow-up protocol after complete resection of PPGLs [12].
2. Pathologic Risk Stratification
To break through the difficulty of pathologic diagnosis of PCC, Thompson used a scoring system,
Pheochromocytoma of the Adrenal Gland Scaled Score (PASS), which consists of 12 parameters and
scores up to 20 points. Tumors with a PASS score ≥4 were defined as having increased metastatic
potential, whereas those with a score <4 were considered not to have metastatic potential [13].
The utility of PASS was validated by seven experienced pathologists that concluded there is significant
interobserver and intraobserver variation and they could not currently recommended PASS for
clinical prognostication [14]. Kimura et al. [15] then developed another scoring system, Grading of
Adrenal Pheochromocytoma and Paraganglioma (GAPP), composed of six parameters that have been
considered prognostic factors in many previous reports, including some from PASS and Kimura’s
own experience.
2.1. GAPP
GAPP is characterized by first evaluating the malignant grade of PCC and sympathetic PGL
together, in contrast to PASS, which is only for evaluating PCC. Next, catecholamine phenotypes
are analyzed and finally, the malignancy is graded as low risk, intermediate risk, or high risk
for metastasis. Thus, predicting patient survival is based on risk grade instead of benign or
malignant PPGLs. Histological grading is based on a scoring system composed of six parameters
(risk factors for metastasis): Histological pattern, cellularity, comedo necrosis, capsular/vascular
invasion, Ki67 labeling index and catecholamine phenotype, with a total of 10 possible points (Table 1).
A score of 0–2 is well, 3–6 is moderately and 7–10 is poorly differentiated types (Table 2). Of these
PPGLs, approximately 70% are well differentiated, which very rarely metastasize and no patients
died of this type of tumor. The well differentiated tumors are compatible with so-called benign
PPGLs. In the remaining PPGLs, approximately 20% are moderately and 10% are poorly differentiated,
with high metastatic potential (60% and 88%, respectively). The five-year survival rates of the patients
are 100%, 67% and 22% for well, moderately and poorly differentiated PPGLs, respectively. Effectively,
a GAPP score of 0–2 is low risk, of 3–6 is intermediate risk and of 7–10 is high risk (Table 3). A clinical
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requirement for risk stratification is urgent as the clinical course of patients with malignant PPGL is
remarkably variable and an individualized approach to patients with metastatic PPGL is warranted [16].
Furthermore, risk stratification is required to tailor the follow-up protocol after complete resection
of PPGL [12]. GAPP could be utilized for urgent clinical requirements, as Koh et al. have validated
GAPP for the prediction of metastatic potentiality [17].
Table 1. Parameters and score in grading of adrenal pheochromocytoma and paraganglioma (GAPP).
Parameters Score
Histological Pattern
Zellballen 0
Large and irregular cell nest 1
Pseudorosette (even focal) 1
Cellularity
Low (less than 150 cells/U *) 0
Moderate (150–250 cells/U *) 1
High (more than 250 cells/U *) 2
Comedo Necrosis
Absence 0
Presence 2
Vascular or Capsular Invasion
Absence 0
Presence 1
Ki67 Labelling Index
Less than 1% 0
1–3% 1
More than 3% 2
Catecholamine Type
Adrenaline type (A **, or A + NA ***) 0
Noradrenaline type (NA, or NA + DA ****) 1
Non-functioning type 0
Total Maximum Score 10
U *: Cells in Unit of 10× 10 mm micrometer under high power field (×400); A **: Adrenaline; NE ***: Noradrenaline;
DA ****: Dopamine.
Table 2. GAPP: Total Score and Grading.
Score Grading
0–2 Well differentiated type
3–6 Moderately differentiated type
7–10 Poorly differentiated type
Table 3. GAPP Score and Risk Stratification.
Total Score
(Points)
Histological Grade
(Frequency) Metastatic Rate 5-Year Survival (%) Risk Stratification
0–2 Well differentiated (68%) 3.6% 100 Low
3–6 Moderately differentiated (22%) 60.0% 66.8 Intermediate
7–10 Poorly differentiated (10%) 88.2% 22.4 High
2.2. Catecholamine Type and Metastasis
PPGLs are characterized by production of catecholamine. Catecholamines, such as adrenaline,
noradrenaline and dopamine, as well as tumor location and ratio of metastasis, are intimately
correlated in PPGLs. Adrenaline-producing tumors, those that produce adrenaline only or
adrenaline plus noradrenaline, are 100% of adrenal gland origin, with a metastatic ratio of 13%.
Noradrenaline-producing PPGLs are those tumors in which noradrenaline only or noradrenaline
plus dopamine are produced; 50% of PCCs and 100% of PGLs are of this type. The metastatic ratio
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is 2 times higher in noradrenaline-type than adrenaline-type tumors in PCCs and approximately
3 times higher in noradrenaline-type tumors in combined PCCs and PGLs (Table 4). Thus,
catecholamine type constitutes an important risk factor. Noradrenaline-producing PPGLs lack
phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts noradrenaline to
adrenaline and are considered to be less differentiated than adrenaline-producing tumors based on
catecholamine synthesis. In addition, dopamine hypersecretion is considered a feature of immaturity
and a marker for malignant PPGLs [18]. Dopamine-producing PPGLs are typically non-functioning;
Eisenhofer et al. [19] reported that the plasma level of methoxytyramine, the O-methylated metabolite
of dopamine, is 4.7-fold higher in patients with metastases than in those without, suggesting its use as
a potential biomarker. The mechanisms underlying non-functioning PPGLs are not fully understood.
A deficiency of catecholamine synthesizing enzymes may partially, but not fully, account for this
phenomenon [20]. Therefore, the correlation of non-functioning PPGLs and patient prognosis should
be further investigated.
Table 4. Catechoamine types, tumor locations and metastasis.
Catecholamine Types Number of Patients Number of Metastasis Ratio of Metastasis (%)
Epinephrine 78 11 14.1
Norepinephrine 79 29 36.7
(Adrenal) (49) (13) (26.5)
(Extra-adrenal) (30) (15) (50.0)
Non-functioning
(Extra-adrenal) 6 1 16.7
Total Number 163 41 25.1
3. Molecular Risk Stratification
There are 20 susceptibility genes for PPGLs at present: SDHA, SDHAF2, SDHC, KIF1B,
TMEM127, FH, NF1, RET, VHL, SDHD, SDHB, MAX, HRAS, ATRX, EPAS1/HIF2A, MEN1,
EGLN1/PDH2, EGLN2/PDH1, MDH2 and IDH1 in various types of mutations including germline
only, germline and somatic, somatic only, somatic and somatic mosaicism and single patients
or families [21,22]. Germline mutations in predisposition genes are found in 25–30% of PPGLs
overall [23]. Germline mutations in succinate dehydrogenase subunit x (SDHx) including SDHA,
SDHB, SDHC, SDHD and SDHAF2 are the most common genetic cause of PPGLs, occurring
in up to 25% of cases [24,25]. The next most commonly associated genes are VHL (4–10%),
RET (1–5%) and NF1 (1–5%) [26]. PGL1 syndrome (SDHD) and PGL2 syndrome (SDHAF2) are
notable for their high frequency of multifocal tumor development and for parent-of-origin inheritance.
PGL4 syndrome (SDHB) is notable for an increased risk of malignant PPGLs. PGL3 syndrome
(SDHC) and PGL5 syndrome (SDHA) are less common [26]. Human hereditary paraganglioma
pheochromocytoma syndrome (HPPS), including SDH types 1–5, is an autosomal dominant disorder
characterized by familial predisposition to PPGLs and occasionally combined with renal cell
carcinomas, gastrointestinal stromal tumors, neuroendocrine tumors of the pancreas and intestine and
rarely, pituitary adenomas [27]. Proportion of gender and age-specific in hereditary PPGL is reported
in Table 5 [28].
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Table 5. Proportion of age and gender in hereditary PPGLs with syndromes.
Syndrome Number GeneMutated
Gender
(Male/Female)
Age Range
(Years; Mean) Pheochromocytoma Paraganglioma
NF1 12 NF1 3/9 29–67 (44.2) 12 0
MEN2 24 RET 8/16 18–76 (35.6) 24 0
VHL 29 VHL 12/13 (4 U) 7–62 (25·6) 21 (3 U) 5
PCC-PGL 36 SDHB 13/12 (11 U) 10–63 (34.6) 11 (7 U) 18
PCC-PGL 5 SDHC 2/3 15–47 (30.6) 0 5
PCC-PGL 61 SDHD 25/35 (1 U) 16–72 (40.9) 5 (3 U) 53
Sporadic 53 None 17/34 (2 U) 12–79 (49.3) 34 (1 U) 18
NF-1: Neurofibromatosis type 1; MEN2: Multiple endocrine neoplasia type 2; VHL: Von Hippel-Lindau disease;
PCC-PGL: Familial paraganglioma-pheochromocytoma syndrome; U: Unknown.
3.1. Immunohistochemistry for Gene Mutations
Loss of SDHB protein immunoreactivity in tumors with SDHx mutation is reported with 100%
sensitivity and 84% specificity [28]. The following studies validated that SDHB immunohistochemistry
can be used for screening of patients with HPPS using paraffin-embedded tumor tissues [29–31].
The SDHB mutation is the only established factor that indicates future metastasis. Therefore, it is
important to perform SDHB immunohistochemistry for all PPGLs except the adrenaline-producing
type. Patients with SDHB-negative tumors should be carefully monitored for a long period of time
due to the high possibility of metastasis.
In addition to SDHx PPGLs, VHL tumors are sometimes SDHB-immunohistochemistry negative
or stain very weakly. The reasons for such phenomenon may be explained such as tumors associated
with SDH deficiency display notable upregulation of hypoxia-responsive genes like VHL and this is
shared by PPGLs associated with mutations in VHL [32,33]. In addition, immunohistochemistry
for SDHA-negative or MAX-negative tumors indicate an SDHA- [34] or MAX-mutation [35,36]
retrospectively. Therefore, if immunohistochemical analysis is negative for SDHB, SDHA, or MAX,
gene analysis should be performed to determine if a mutation is actually present, particularly in
younger patients or patients with bilateral, extra-adrenal, or familial PPGLs.
3.2. Differential Diagnosis and Risk Stratification
A microarray-gene expression profile demonstrates that Cluster 1 and Cluster 2 clearly
differentiate between and correlate with types of genes, signaling pathways and tumor
phenotypes [20,23,37,38]. Furthermore, Cluster and GAPP produce very similar results regarding
genotype and phenotype correlation (Table 6). The combined data of Cluster and GAPP [15,19,36] may
greatly contribute to identifying and selecting the type of therapy and treatment patients receive.
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Table 6. Correlation of Cluster Stratification and GAPP.
Cluster 1 Cluster 1 Cluster 2
Gene
SDH x (SDHA, B, C,D),
SDHAF2, HIF2, KIF1B,
PHD2, HRAS, FH, HIF-1
VHL Sporadic
Noradrenergic
RET, NF1, MAX,
TMEM127,
Sporadic adrenergic
Signaling pathways Pseudo hypoxia (HIF-1a) &aberrant VEGF signaling
Kinase signalling:
PI3 kinase/AKT,
RAS/RAF/ERK, &
mTorC1/p70S6K
Catecholamine type DA, mixed DA & NA Noradrenaline Adrenaline
Secretory phenotype Immature Immature Mature
Tumor location Extra-adrenal Adrenal & Extra-adrenal Adrenal
Age of presentation Early (under 30 year-old) Early Late
Metastasis Frequent Occasional Rare
Metastatic risk by GAPP Intermediate–High Low–Intermediate Low
Cluster stratification: Microarray-gene expression profiling; DA: Dopamine; NA: Noradrenaline; A: Adrenaline.
4. Flowchart for Differential Diagnosis
Pathological diagnosis of PPGLs is sometimes difficult for general pathologists due to their very
low incidence and histological variety, particularly in cases of non-functioning, or catecholamine
data are unknown tumors. For example, adrenocortical carcinoma and neuroendocrine tumors are
sometimes misdiagnosed as PPGLs. Gastrointestinal stromal tumors, adult neuroblastoma and alveolar
soft part sarcoma are rarely needed for differential diagnosis. Immunohistochemistry is the most useful
tool for differential diagnosis. All functioning and non-functioning PPGLs express chromogranin A
(CgA) and dopamine β-hydroxylase (DBH) [20]. CgA is an essential protein for PPGLs as well as for
normal adrenal medulla. Thus, if immunohistochemistry for CgA is negative, PPGLs should be ruled
out. Other neuroendocrine markers such as synaptophysin and neural cell adhesion molecule (CD56)
are general markers for neuroendocrine tumors besides PPGLs, as well as some adrenocortical tumors.
Adrenocortical carcinomas or neuroendocrine tumors of other organs are sometimes misdiagnosed
as non-functioning PPGLs. Thus, if only synaptophysin and CD56 are positive, this is not sufficient
evidence for a diagnosis of PPGL. Tyrosine hydroxylase (TH) and DBH are essential enzymes for
catecholamine synthesis and both antibodies are useful for identification of catecholamine-producing
tumors. However, some non-functioning PPGLs including only dopamine-producing or SDHB-related
PPGLs lack TH immunoreactivity [39,40], but constantly positive for DBH, making DBH a better
marker than TH for identification of PPGLs [20,36] (Figure 1). A flowchart for pathologically differential
diagnosis of PPGLs is presented (Figure 2).
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Figure 1. Non-functioning retroperitoneal paraganglioma. (A) This tumor shows large irregular 
zellballen pattern, high cellularity, comedo necrosis, vascular invasion, 14% of Ki67 labelling index 
and total score of CAPP is 9 points; (B) Chromogranin A immunostaining shows dot-like reactivity at 
Golgi area of tumor cells; (C) Tyrosine hydroxylase immunohistochemistry shows negative staining 
in all tumor cells. Inset is internal control of sympathetic ganglion cells adjacent to the tumor; (D) 
Dopamine beta-hydroxylase immunostaining shows positive reaction in tumor cells even like this 
non-functioning paraganglioma. 
Figure 1. Non-functioning retroperitoneal paraganglioma. (A) This tumor shows large irregular
zellballen pattern, high cellularity, comedo necrosis, vascular invasion, 14% of Ki67 labelling index
and total score of CAPP is 9 points; (B) Chromogranin A immunostaining shows dot-like reactivity at
Golgi area of tumor cells; (C) Tyrosine hydroxylase immunohistochemistry shows negative staining
in all tumor cells. Inset is internal control of sympathetic ganglion cells adjacent to the tumor;
(D) Dopamine beta-hydroxylase immunostaining shows positive reaction in tumor cells even like this
non-functioning paraganglioma.
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Figure 2. Flowchart for differential diagnosis of PPGLs based on tumor location, catecholamine production, and immunohistochemistry. CA: Catecholamine; CgA: 
Chromogranin A; DBH: Dopamine β-hydroxylase; SDHB: Succinate dehyrogenase subunit B; PCC: Pheochromocytoma; PGL: Paraganglioma; GAPP: Grading of adrenal 
pheochromocytoma and paraganglioma; SP: Synaptophysin; CD56: Neural cell adhesion molecule; NETs: Neuroendocrine tumors; NB: Neuroblastoma; RCC: Renal cell 
carcinoma; GIST: Gastrointestinal stromal tumor; ASPS: Alveolar soft part sarcoma. 
Figure 2. Flowchart for differential diagnosis of PPGLs based on tumor location, catecholamine production, and i munohistochemistry. CA: Catecholamine;
CgA: Chromogranin A; DBH: Dopamine β-hydroxylase; DHB: Succinate dehyrogenase subunit B; CC: Pheochromocytoma; PGL: P raganglioma; GAPP: Grading of
adrenal pheochromocytoma and paraganglioma; SP: Sy aptophysin; CD56: Neural cell adhesion molecule; NETs: Neuroendocrine tumo s; NB: Neuroblastom ;
RCC: Renal cell c rcinoma; GIST: Gastrointestinal stromal tumor; ASPS: Alveolar soft part sarcoma.
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5. Summary and Conclusions
Recent research on PPGLs shows remarkable progress and comprehensive study of clinical,
molecular, biochemical and pathological investigations revealed some of the complicated problems
associated with PPGLs. Cluster stratification and GAPP intimately correlate which means genotype
and phenotype correlation becomes clear in hereditary PPGLs. Immunohistochemistry of SDHB,
SDHA, and MAX is a powerful tool for screening these hereditary PPGLs. Catecholamine are specific
products in PPGLs and they have been focused for diagnosis and therapy by endocrinology and
radiology area. Pathologists should also pay attention to biochemical features of PPGLs to make
precise and useful diagnosis for patients. Non-functioning PPGLs including SDHB mutation in
part but not all are interested in the view point of cell maturation and function of catecholamine
synthesis and secretion. Many issues are still remained for further research, in particular, clarifying
the mechanism of tumor metastasis and developing a therapy for highly malignant PPGLs in which
responsible genes are not yet determined.
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